Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 14Thoracic 4Gynecologic 2Breast 2Sarcoma 1Genitourinary 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Recurrence 1

Interventions

Carboplatin 510Cisplatin 410Pemetrexed 400Radiotherapy 285Docetaxel 244Paclitaxel 227pembrolizumab 226Gemcitabine 198Drug Therapy 191Bevacizumab 190Erlotinib Hydrochloride 189Radiosurgery 177Nivolumab 168Etoposide 155durvalumab 154osimertinib 126atezolizumab 109Gefitinib 96Blood Specimen Collection 93Magnetic Resonance Spectroscopy 91Vinorelbine 90anlotinib 88Surgical Procedures, Operative 85Ipilimumab 62Immunotherapy 62Surveys and Questionnaires 60sintilimab 59Specimen Handling 59tislelizumab 58Irinotecan 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Receptor Protein-Tyrosine Kinases × Thoracic × Clear all
NCT01515969 2016-07-12

Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)

Stanford University

Phase 1 Terminated
9 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT00633724 2013-08-15

Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer

Fukushima Medical University

Phase 1 Completed
9 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00874588 2013-08-15

Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer

Fukushima Medical University

Phase 1 Completed
6 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00673777 2008-05-14

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer

Tokyo University

Phase 1/2 Unknown
14 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡